Invention Grant
- Patent Title: Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells
-
Application No.: US16529159Application Date: 2019-08-01
-
Publication No.: US11077143B2Publication Date: 2021-08-03
- Inventor: Hans G. Klingemann , Laurent H. Boissel , Abhijit Dandapat
- Applicant: NANTKWEST, INC.
- Applicant Address: US CA San Diego
- Assignee: NANTKWEST, INC.
- Current Assignee: NANTKWEST, INC.
- Current Assignee Address: US CA San Diego
- Agency: Umberg Zipser LLP
- Agent Martin Fessenmaier
- Main IPC: A61K35/17
- IPC: A61K35/17 ; A61P35/00 ; C07K14/735 ; C07K14/725 ; A61P35/04 ; C07K14/54 ; C07K16/28 ; C07K14/55
Abstract:
Provided herein are compositions of NK-92™ cells that express a combination of PD-L1 CAR, CD16 and IL2, and the method of using these cells to reduce tumor cells and cells in tumor microenvironment (e.g., MDSCs or TAMs) and treat cancer.
Information query
IPC分类:
